Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

“Troponinitis” or “Troponinemia”: Terms that Trivialize Troponin Elevation Without a Specified Diagnosis

Troponin elevation is a common finding in acute patients admitted by an emergency service, even in the absence of an acute coronary event. There are patients in whom we simply cannot identify the origin of such troponin elevation. Initially, we relied on this marker as an exclusive marker of acute coronary syndrome. In consequence, many patients with troponin elevation sooner or later ended up in the cath lab, despite their inconclusive electrocardiograms and signs and symptoms of other diseases.

DETO2X-AMI: el O2 suplementario no aporta beneficios en pacientes con sospecha de infartoWe have encountered so many normal coronary arteries in this setting that somewhere along the line we popularized the terms “troponitis” and “troponinemia”.

 

This study aimed to investigate the association between troponin elevation and long-term clinical prognosis in acute patients admitted in the emergency room with suspected acute coronary syndrome, who were ultimately discharged without a specified diagnosis.


Read also: The Physiopathology Behind Valve Degeneration in TAVR.


This study analyzed retrospectively the 48,872-patient cohort from the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) study. Patients were stratified according to their troponin levels into cohorts with troponin levels less than or equal to the cutoff (99th percentile), and all levels above the cutoff were separated by tertiles.

 

Positive troponin levels were identified in 20.1% of patients (n = 9800). As expected, the prevalence of cardiovascular risk factors as well as noncardiovascular comorbidities increased across higher tertiles.


Read also: Bundle Branch Block and Need for Permanent Pacemaker, a Major Challenge after TAVR.


In total, 15.4% of such patients with positive troponin levels who were discharged from their index hospitalization without a specified diagnosis had more events (cardiovascular death, acute myocardial infarction, readmission for heart failure, or stroke) over a mean follow-up of almost 5 years.

 

Conclusion

Troponin elevation is associated with cardiovascular and noncardiovascular comorbidities, and it predicts future events in acutely admitted patients, in whom no definite diagnosis could be established during their index hospitalization. The terms “troponinitis” and “troponinemia” trivialize the prognostic value of this marker and should be avoided, even if we cannot explain this phenomenon.

 

Original title: Cardiac Troponin Elevation in Patients Without a Specific Diagnosis.

Reference: Kai M. Eggers et al. J Am Coll Cardiol 2019;73:1-9.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...